Cybin (HELP) Water Tower Research Fireside Chat summary

Introduction and agenda

• The session featured a discussion with the CEO of a late-stage neuropsychiatry company focused on novel mental health treatments.

Background and experience of the speaker

• The CEO has 35 years of experience in building drug development companies, emphasizing the incremental nature of most drug development and the unique challenges in psychiatric disorders.

Current industry trends

• There is a surge in research targeting hard-to-treat mental health disorders, with a focus on innovative clinical approaches for depression and anxiety.

• Existing psychiatric infrastructure is expanding, supporting the rollout of new interventional treatments.